Oxford BioTherapeutics (OBT), a clinical-stage oncology company with a pipeline of immuno-oncology (IO) and Antibody Drug Conjugate (ADC)-based therapies, has entered a multi-year collaboration with Roche to discover novel potentially first-in-class antibody-based therapeutics for the treatment of cancer. Under the terms of the agreement, targets will be identified via OBT’s recently launched OGAP-Verify discovery platform and validated through the research collaboration. Any further research...